Evidence map›Paper›PMID 20401461›Full record

ArticleDiabetologia2010

Sex dimorphic actions of rosiglitazone in generalised peroxisome proliferator-activated receptor-gamma (PPAR-gamma)-deficient mice.

S Z Duan, M G Usher, E L Foley, D S Milstone, F C Brosius, R M Mortensen

Erratum issuedOpen access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetologia, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. A brain-specificLife science alliance · 2021
    Article
  5. Review
  6. Article
  7. Is the Mouse a Good Model of Human PPARγ-Related Metabolic Diseases?International journal of molecular sciences · 2016
    Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

  • Erratum issued
5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

S Z DuanDepartment of Internal Medicine, Nephrology Division, University of Michigan Medical School, Ann Arbor, MI, USA.
M G Usher
E L Foley
D S Milstone
F C Brosius
R M Mortensen
University of Michigan–Ann Arbor · USHarvard University · US

Funding

Vascular smooth muscle glucose transport in hypertensionR01HL065567 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI BROSIUS, FRANK C · 2001 to 2011
$2.7M
PPARg in trophoblast and placental developmentR01HD040895 · NICHD · BRIGHAM AND WOMEN'S HOSPITAL · PI MILSTONE, DAVID S · 2003 to 2007
$1.5M
Metabolic responsive factors in cardiovascular diseaseR01HL083201 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MORTENSEN, RICHARD M · 2006 to 2009
$1.5M
NHLBI NIH HHS R01 HL065567NHLBI NIH HHS R01 HL083201NHLBI NIH HHS R01HL083201NICHD NIH HHS R01 HD040895NICHD NIH HHS R01HD040895
6 · The paper itself

Abstract

aims/hypothesisThe aim of this study was to determine the dependency on peroxisome proliferator-activated receptor-gamma (PPAR-gamma) of insulin sensitisation and glucose homeostasis by thiazolidinediones using a global Ppar-gamma (also known as Pparg)-knockout mouse model.

methodsGlobal Mox2-Cre-Ppar-gamma-knockout (MORE-PGKO) mice were treated with rosiglitazone and analysed for insulin sensitivity and glucose metabolism. Metabolic and hormonal variables were determined. Adipose and other tissues were measured and analysed for gene expression.

resultsRosiglitazone induced regrowth of fat in female but not male MORE-PGKO mice, and only in specific depots. Insulin sensitivity increased but, surprisingly, was not associated with the typical changes in adipokines, plasma NEFA or tissue triacylglycerol. However, increases in alternatively activated macrophage markers, which have been previously associated with metabolic improvement, were observed in the regrown fat. Rosiglitazone improved glucose homeostasis but not insulin sensitivity in male MORE-PGKO mice, with further increase of insulin associated with an apparent expansion of pancreatic islets. CONCLUSIONS/

interpretationStimulating fat growth by rosiglitazone is sufficient to improve insulin sensitivity in female mice with 95% PPAR-gamma deficiency. This increase in insulin sensitivity is not likely to be due to changes typically seen in adipokines or lipids but may involve changes in macrophage polarisation that occur independent of PPAR-gamma. In contrast, rosiglitazone improves glucose homeostasis in male mice with similar PPAR-gamma deficiency by increasing insulin production independent of changes in adiposity. Further, the insulin-sensitising effect of rosiglitazone is dependent on PPAR-gamma in this male lipodystrophic model.

Indexed as

Sex CharacteristicsAdipose TissueAnimalsBlotting, SouthernBlotting, WesternEnzyme-Linked Immunosorbent AssayFatty Acids, NonesterifiedFemaleHypoglycemic AgentsInsulin ResistanceLipid MetabolismMaleMiceMice, KnockoutPPAR gammaRosiglitazoneFatty Acids, NonesterifiedHypoglycemic AgentsPPAR gammaRosiglitazoneThiazolidinediones

Identifiers

PMID20401461
PMCPMC2896206
OpenAlexW2017656310

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.